Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the IUPAC name (5S)-2-{[(1S)-1-(4-Fluorophenyl)ethyl]amino}-5-(2-hydroxypropan‑2‑yl)‑5‑methyl‑4,5-dihydro‑1,3-thiazol‑4-one. It belongs to the class of fluorobenzenes and thiazoles. The molecule has been studied as an experimental agent and is not approved for clinical use in any country. Its primary mechanism of action is as an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1 (11β-HSD type 1), an enzyme involved in glucocorticoid metabolism. Inhibition of this enzyme has been investigated for potential therapeutic effects in metabolic disorders such as diabetes and obesity[2]. There are no known brand names or marketed formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5S)-2-{[(1S)-1-(4-Fluorophenyl)ethyl]amino}-5-(2-hydroxy-2-propanyl)-5-methyl-1,3-thiazol-4(5H)-one.